The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
Open accessAbstract
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow (BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen receptor (CAR) T cells] within the first year of treatment was associated with a hazard ratio (HR) for relapse of 4.5 [95% confidence interval (CI), 2.03–9.97; P < 0.001]. Multivariate analysis at day 28 showed independent associations of BMNGS-MRD >0 (HR = 4.87; 95% CI, 2.18–10.8; P < 0.001) and B-cell recovery (HR = 3.33; 95% CI, 1.44–7.69; P = 0.005) with relapse. By 3 months, the BMNGS-MRD HR increased to 12 (95% CI, 2.87–50; P < 0.001), whereas B-cell recovery was not independently predictive (HR = 1.27; 95% CI, 0.33–4.79; P = 0.7). Relapses occurring with persistence of B-cell aplasia were largely CD19− (23/25: 88%). Detectable BMNGS-MRD reliably predicts risk with sufficient time to consider approaches to relapse prevention such as hematopoietic cell transplantation (HCT) or second CAR-T cell infusion. Significance: Detectable disease by BMNGS-MRD with or without B-cell aplasia is highly predictive of relapse after tisagenlecleucel therapy for ALL. Clonotypic rearrangements used to follow NGS-MRD did not change after loss of CD19 or lineage switch. High-risk patients identified by these biomarkers may benefit from HCT or investigational cell therapies. See related commentary by Ghorashian and Bartram, p. 2. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“In practice, B-cell aplasia has been used as a pharmacodynamic indicator of CAR-T functional persistence (5).”
MethodSelf-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citation
Cited by
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210859 · Cited by 561
Laetsch, T. W., Maude, S. L., Rives, S., Hiramatsu, H., Bittencourt, H., Bader, P., Baruchel, A., Boyer, M., De Moerloose, B., Qayed, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00642 · Cited by 383
Self-citationBai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Self-citationAwasthi, R., Maier, H. J., Zhang, J., & Lim, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2210046 · Cited by 123
Self-citation
Metadata
- Authors
- Pulsipher, M. A., Han, X., Maude, S. L., Laetsch, T. W., Qayed, M., Rives, S., Boyer, M. W., Hiramatsu, H., Yanik, G. A., Driscoll, T., Myers, G. D., Bader, P., Baruchel, A., Buechner, J., Stefanski, H. E., Kalfoglou, C., Nguyen, K., Waldron, E. R., Thudium Mueller, K., Maier, H. J., Kari, G., & Grupp, S. A.
- Venue
- Blood Cancer Discovery
- Published
- 2021-12-01
- Volume
- 3
- Issue
- 1
- Pages
- 66-81
- ISSN
- 2643-3230 (ISSN-L)
- 2643-3249
- OpenAlex
- W3214897392
- Cited by
- 204
- References
- 3
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1158/2643-3230.bcd-21-0095
- The paper
- Pulsipher, M. A., Han, X., Maude, S. L., Laetsch, T. W., Qayed, M., Rives, S., Boyer, M. W., Hiramatsu, H., Yanik, G. A., Driscoll, T., Myers, G. D., Bader, P., Baruchel, A., Buechner, J., Stefanski, H. E., Kalfoglou, C., Nguyen, K., Waldron, E. R., Thudium Mueller, K., . . . Grupp, S. A. (2022). Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-21-0095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.